Spots Global Cancer Trial Database for Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
Official Title: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 160 in Subjects With Non-Small Cell Lung Cancer
Study ID: NCT04822298
Interventions
Study Description
Brief Summary: This study aims to evaluate the safety and tolerability of AMG 160 and to evaluate the maximum tolerated dose (MTD) or the recommended phase 2 dose (RP2D).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Chris OBrien Lifehouse, Camperdown, New South Wales, Australia
Landeskrankenhaus Salzburg, Salzburg, , Austria
Universitaetsklinikum Allgemeines Krankenhaus Wien, Wien, , Austria
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
